Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review
SUMMARY INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly described virus responsible for the outbreak of the coronavirus disease 2019 (Covid-19), named by the World Health Organization (WHO) in February/2020. Patients with Covid-19 have an incidence of acute respiratory distress syndrome (ARDS) of 15.9-29% and sepsis is observed in all deceased patients. Moreover, disseminated intravascular coagulation (DIC) is one of the major underlying causes of death among these patients. In patients with DIC, there is a decrease in fibrinogen and an increase in D-dimer levels. Some studies have shown that fibrinogen and one of its end products, D-dimer, might have a predictive value for mortality in patients with non-Covid sepsis secondary to complications of DIC. Therefore, anticoagulation, considering its mortality benefits in cases of non-Covid sepsis, may also have an important role in the treatment of Covid-19. METHODS We reviewed the literature of all studies published by April 2020 on patients infected with Covid-19. Our review was limited to D-dimer and fibrinogen changes and anticoagulation recommendations. RESULTS Anticoagulation therapy can be started following the DIC diagnosis in Covid-19 patients despite the bleeding risks. In addition, the current evidence suggests a routine use of anticoagulation, particularly in patients with higher D-dimer levels (> 3.0 μg/mL). CONCLUSION Covid-19 is a systemic, hypercoagulable disease requiring more studies concerning treatment. Aanticoagulation is still an issue to be studied, but D-dimer rise and disease severity are the indicative factors to start treatment as soon as possible.
Main Authors: | , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Médica Brasileira
2020
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600842 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0104-42302020000600842 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0104-423020200006008422020-07-17Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature reviewHayıroğlu,Mert İlkerÇınar,TufanTekkeşin,Ahmet İlker Coronavirus Infections Anticoagulants Disseminated intravascular coagulation Fibrin fibrinogen degradation products Blood Coagulation SUMMARY INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly described virus responsible for the outbreak of the coronavirus disease 2019 (Covid-19), named by the World Health Organization (WHO) in February/2020. Patients with Covid-19 have an incidence of acute respiratory distress syndrome (ARDS) of 15.9-29% and sepsis is observed in all deceased patients. Moreover, disseminated intravascular coagulation (DIC) is one of the major underlying causes of death among these patients. In patients with DIC, there is a decrease in fibrinogen and an increase in D-dimer levels. Some studies have shown that fibrinogen and one of its end products, D-dimer, might have a predictive value for mortality in patients with non-Covid sepsis secondary to complications of DIC. Therefore, anticoagulation, considering its mortality benefits in cases of non-Covid sepsis, may also have an important role in the treatment of Covid-19. METHODS We reviewed the literature of all studies published by April 2020 on patients infected with Covid-19. Our review was limited to D-dimer and fibrinogen changes and anticoagulation recommendations. RESULTS Anticoagulation therapy can be started following the DIC diagnosis in Covid-19 patients despite the bleeding risks. In addition, the current evidence suggests a routine use of anticoagulation, particularly in patients with higher D-dimer levels (> 3.0 μg/mL). CONCLUSION Covid-19 is a systemic, hypercoagulable disease requiring more studies concerning treatment. Aanticoagulation is still an issue to be studied, but D-dimer rise and disease severity are the indicative factors to start treatment as soon as possible.info:eu-repo/semantics/openAccessAssociação Médica BrasileiraRevista da Associação Médica Brasileira v.66 n.6 20202020-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600842en10.1590/1806-9282.66.6.842 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Hayıroğlu,Mert İlker Çınar,Tufan Tekkeşin,Ahmet İlker |
spellingShingle |
Hayıroğlu,Mert İlker Çınar,Tufan Tekkeşin,Ahmet İlker Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review |
author_facet |
Hayıroğlu,Mert İlker Çınar,Tufan Tekkeşin,Ahmet İlker |
author_sort |
Hayıroğlu,Mert İlker |
title |
Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review |
title_short |
Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review |
title_full |
Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review |
title_fullStr |
Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review |
title_full_unstemmed |
Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review |
title_sort |
fibrinogen and d-dimer variances and anticoagulation recommendations in covid-19: current literature review |
description |
SUMMARY INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly described virus responsible for the outbreak of the coronavirus disease 2019 (Covid-19), named by the World Health Organization (WHO) in February/2020. Patients with Covid-19 have an incidence of acute respiratory distress syndrome (ARDS) of 15.9-29% and sepsis is observed in all deceased patients. Moreover, disseminated intravascular coagulation (DIC) is one of the major underlying causes of death among these patients. In patients with DIC, there is a decrease in fibrinogen and an increase in D-dimer levels. Some studies have shown that fibrinogen and one of its end products, D-dimer, might have a predictive value for mortality in patients with non-Covid sepsis secondary to complications of DIC. Therefore, anticoagulation, considering its mortality benefits in cases of non-Covid sepsis, may also have an important role in the treatment of Covid-19. METHODS We reviewed the literature of all studies published by April 2020 on patients infected with Covid-19. Our review was limited to D-dimer and fibrinogen changes and anticoagulation recommendations. RESULTS Anticoagulation therapy can be started following the DIC diagnosis in Covid-19 patients despite the bleeding risks. In addition, the current evidence suggests a routine use of anticoagulation, particularly in patients with higher D-dimer levels (> 3.0 μg/mL). CONCLUSION Covid-19 is a systemic, hypercoagulable disease requiring more studies concerning treatment. Aanticoagulation is still an issue to be studied, but D-dimer rise and disease severity are the indicative factors to start treatment as soon as possible. |
publisher |
Associação Médica Brasileira |
publishDate |
2020 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600842 |
work_keys_str_mv |
AT hayıroglumertilker fibrinogenandddimervariancesandanticoagulationrecommendationsincovid19currentliteraturereview AT cınartufan fibrinogenandddimervariancesandanticoagulationrecommendationsincovid19currentliteraturereview AT tekkesinahmetilker fibrinogenandddimervariancesandanticoagulationrecommendationsincovid19currentliteraturereview |
_version_ |
1756410068771799040 |